Skip to main content

Table 2 Comparison of PD and NPD using landmark analysis at 3 months

From: Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Characteristics PD Group N (%)
n = 49
NPD Group N (%)
n = 39
p-value
Mean age, years (SD) 66 (10.20) 64 (9.61) 0.401
Male Gender 33 (67) 33 (85) 0.107
ECOG PS    0.106
 0 23 (52) 10 (27)
 1 15 (34) 18 (49)
  > 2 6 (14) 9 (24)
IMDC Risk Group    0.139
 Favorable 8 (17) 4 (10)
 Intermediate 35 (73) 24 (63)
 Poor 5 (10) 10 (26)
Prior Nephrectomy 35 (97) 30 (97) 1.000
No of prior systemic therapies, median, No. (range)
No of prior systemic therapies    0.404
 1 25 (51) 15 (38)
 2 10 (20) 14 (36)
 3 10 (20) 6 (15)
  > 4 3 (6) 4 (10)
Common prior systemic therapies
 Sunitinib 38 (78) 24(61) 0.161
 Pazopanib 15 (31) 15 (38) 0.586
 Axitinib 18 (37) 17 (44) 0.665
Sites of metastases at baseline
 Brain 7 (18) 7 (14) 0.862
 Bones 13 (33) 24 (49) 0.208
 Lungs 33 (85) 31 (63) 0.046
 Liver 14 (36) 12 (24) 0.352
 Lymph Nodes 31 (79) 26 (53) 0.019
 Pleural 13 (33) 5 (10) 0.016
 Adrenal 9 (23) 11 (22) 1.000
  1. Two patients were excluded from this analysis because of lack data regarding their PD status